Skip to main content
. 2020 Mar 23;10(3):e034712. doi: 10.1136/bmjopen-2019-034712

Table 3.

Trial schedule—outcomes (pro: patient-reported outcomes)

Visit 1
Day 0
Randomisation
Visit 2
Day 7 (±1)
Visit 3
Day 14 (±1)
End of intervention
Daily online questionnaires 1 month after delivery
PUQE-24 score PRO PRO PRO PRO
PUQE well-being score PRO PRO PRO PRO
Nausea VAS PRO PRO PRO PRO
Daily vomiting episodes PRO PRO PRO PRO
Administration of trial medication PRO
Administration of rescue medication PRO
Side effects Registered by trial personnel Registered by trial personnel Registered by trial personnel PRO
NVPQOL PRO PRO PRO
HELP-score PRO PRO PRO
EQ5D-5L PRO PRO PRO
Modified PSQI PRO PRO PRO
Patient satisfaction with treatment VAS PRO PRO
Patient consideration of termination of pregnancy PRO PRO PRO
Request for dosage increase Registered by trial personnel
Request for continued treatment Registered by trial personnel
Days on sick leave PRO PRO
Intravenous fluid therapy PRO PRO
Days of hospitalisation PRO PRO
Weight Measured by trial personnel Measured by trial personnel Measured by trial personnel
Pregnancy outcome including possible malformation and hospitalisation of the new-born Collected from medical record
Treatment failure Registered by trial personnel at time of event

PUQE, Pregnancy Unique Quantification of Emesis; VAS, visual analogue score.